title: Cardiac amyloidosis as a potential risk factor for transapical transcatheter aortic valve implantation.
abstract: Transcatheter aortic valve implantation via transarterial or transapical access is an alternative therapy to treat high-risk patients with severe symptomatic aortic stenosis. Despite growing experience, procedural complications may still occur. We herein report an 86-year-old female patient with fatal left ventricular rupture after transapical transcatheter aortic valve implantation with an Edwards Sapien prosthesis due to severe cardiac amyloidosis.
authors.affiliation: Institute of Forensic Medicine, Salzburg University, Salzburg, Austria.
authors.forename: Fabio C
authors.initials: FC
authors.lastname: Monticelli
authors.forename: Sebastian N
authors.initials: SN
authors.lastname: Kunz
authors.forename: Thomas
authors.initials: T
authors.lastname: Keller
authors.forename: Sabine
authors.initials: S
authors.lastname: Bleiziffer
mesh_terms: D000369:Aged, 80 and over; D000686:Amyloidosis / Q000150:complications*; D001024:Aortic Valve Stenosis / Q000601:surgery*; D009202:Cardiomyopathies / Q000150:complications*; D017809:Fatal Outcome; D005260:Female; D006333:Heart Failure / Q000209:etiology; D006341:Heart Rupture / Q000209:etiology*; D019918:Heart Valve Prosthesis Implantation / Q000379:methods*; D006352:Heart Ventricles; D006801:Humans; D011183:Postoperative Complications / Q000209:etiology*; D012307:Risk Factors; D012720:Severity of Illness Index